Patents by Inventor John Piwinski

John Piwinski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20260151383
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R100, p, ring A, L, R22?, R22, R32, and R33 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of a disease or disorder that is treatable by administration of an aldehyde dehydrogenase (e.g., ALDH1a3 and/or ALDH1a2) inhibitor.
    Type: Application
    Filed: October 24, 2023
    Publication date: June 4, 2026
    Inventors: Mark ESPOSITO, John PROUDFOOT, John PIWINSKI
  • CARBONIC ANHYDRASE ENZYME INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20260078111
    Abstract: Provided herein are novel compounds, such as a compound of Formula I or Formula A: or a salt thereof, wherein R1-R3, L1, R10, ring A and ring B have any of the values described in the specification, as well as compositions comprising the novel compounds herein. The compounds are typically carbonic anhydrase inhibitors and are useful for the prophylactic or therapeutic treatment of a disease or condition mediated by a carbonic anhydrase enzyme.
    Type: Application
    Filed: December 7, 2023
    Publication date: March 19, 2026
    Applicants: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, NEMAGEN DISCOVERIES, INC.
    Inventors: Mark C. SIRACUSA, Jacques Y. ROBERGE, John A. GILLERAN, John PIWINSKI
  • SUBSTITUTED HETEROCYCLES AS ALDEHYDE DEHYDROGENASE INHIBITORS
    Publication number: 20240343709
    Abstract: Provided herein are novel heterocyclic compounds, for example, compounds of Formula (IV-C). Also provided herein are pharmaceutical compositions comprising the compounds and methods of using the same, for example, in inhibiting aldehyde dehydrogenases, retinoid pathway activation, and/or for treating various cancers, cancer metastasis, type 2 diabetes, pulmonary arterial hypertension (PAH) or neointimal hyperplasia (NIH) or as a male contraceptive.
    Type: Application
    Filed: June 18, 2024
    Publication date: October 17, 2024
    Inventors: Mark ESPOSITO, John PROUDFOOT, Yibin KANG, John PIWINSKI
  • Substituted heterocycles as aldehyde dehydrogenase inhibitors
    Patent number: 12054475
    Abstract: Provided herein are novel heterocyclic compounds, for example, compounds of Formula (IV-C). Also provided herein are pharmaceutical compositions comprising the compounds and methods of using the same, for example, in inhibiting aldehyde dehydrogenases, retinoid pathway activation, and/or for treating various cancers, cancer metastasis, type 2 diabetes, pulmonary arterial hypertension (PAH) or neointimal hyperplasia (NIH) or as a male contraceptive.
    Type: Grant
    Filed: October 17, 2023
    Date of Patent: August 6, 2024
    Assignees: KayoThera Inc., The Trustees of Princeton University
    Inventors: Mark Esposito, John Proudfoot, Yibin Kang, John Piwinski
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20240132469
    Abstract: Provided herein are novel heterocyclic compounds, for example, compounds having Formula I, I-P, II, II-P, III, or IV. Also provided herein are pharmaceutical compositions comprising the compounds and methods of using the same, for example, in inhibiting aldehyde dehydrogenases, retinoid pathway activation, and/or for treating various cancers, cancer metastasis, type 2 diabetes, pulmonary arterial hypertension (PAH) or neointimal hyperplasia (NIH) or as a male contraceptive.
    Type: Application
    Filed: October 17, 2023
    Publication date: April 25, 2024
    Applicants: KayoThera Inc., The Trustees of Princeton University
    Inventors: Mark ESPOSITO, John PROUDFOOT, Yibin KANG, John PIWINSKI
  • Piperazino derivatives as neurokinin antagonists
    Patent number: 5798359
    Abstract: The invention relates to compounds of the formulas ##STR1## wherein Z, R.sub.c, y, x, l.sub.1, l.sub.2, l.sub.3, u, R.sub.4, R.sub.c', n, R.sub.1, R.sub.2, and R.sub.3, are as described herein. These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: August 25, 1998
    Assignee: Schering Corporation
    Inventors: Ho-Jane Shue, Neng-Yang Shih, John Piwinski, Xiao Chen, David J. Blythin
  • Piperazino derivatives as neurokinin antagonists
    Patent number: 5719156
    Abstract: The invention relates to compounds of the formulas ##STR1## wherein Z, R.sub.c, y, x, l.sub.1, l.sub.2, l.sub.3, u, R.sub.4,R.sub.c', n, R.sub.1, R.sub.2, and R.sub.3, are as described herein. These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: February 17, 1998
    Assignee: Schering Corporation
    Inventors: Ho-Jane Shue, Neng-Yang Shih, John Piwinski, Xiao Chen, David J. Blythin